The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.
The Scottish Medicines Consortium has accepted fam-trastuzumab deruxtecan-nxki as a treatment option for adult patients with HER2-positive unresectable or metastatic breast cancer who have previously received 2 or more anti–HER2-based therapies.
The FDA has granted priority review to the supplemental biologics license application of fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti–HER2-based regimen.1
Sara M. Tolaney, MD, MPH, sheds light on zanidatamab and the data reported with the agent in combination with chemotherapy for the treatment of patients with HER2-positive breast cancer.
The combination of tucatinib, trastuzumab, and capecitabine continued to produce an improvement in overall survival compared with trastuzumab/capecitabine alone in patients with HER2-positive metastatic breast cancer who had stable or active brain metastases.
The European Medicines Agency has validated the Type II Variation application for fam-trastuzumab deruxtecan-nxki as a treatment for adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received 1 or more anti–HER2-based regimens.
A supplemental new drug application has been submitted to Japan’s Ministry of Health, Labour, and Welfare or the use of fam-trastuzumab deruxtecan-nxki as a treatment in select patients with HER2-positive unresectable or recurrent breast cancer.
The first patient with high-risk, early-stage HER2-positive breast cancer has received a dose of neoadjuvant fam-trastuzumab deruxtecan-nxki as part of the global, phase 3 DESTINY-Breast11 trial.
Sara A. Hurvitz, MD, discusses the results of subgroup analyses from the phase 3 DESTINY-Breast03 trial in patients with HER2-positive metastatic breast cancer.
Prior research has shown that the combination of trastuzumab deruxtecan plus pertuzumab may be superior to T-trastuzumab deruxtecan alone in patients with HER2-positive metastatic breast cancer and the combination is now under examination in the phase 3 DESTINY-Breast09 trial.
Deborah L. Toppmeyer, MD, discusses clinical trials involving treatments for HER2-positive and triple-negative breast cancer, as well as the importance of making these trials accessible to all patient populations in an attempt to address disparities.
Neil Vasan, MD, PhD, discussed the emergence of de-escalated treatment strategies for patients with HER2-positive breast cancer, pivotal trials that have shifted standards in clinical practice, and next steps for research.